Hyqvia 2400 Unit (Hyaluronidase (Human Recombinant) SOLUTION) 2400 UNIT

HYQVIA 2400 Unit is a subcutaneous solution containing hyaluronidase (human recombinant). It is used to facilitate the absorption of other injected medications. Learn more about its uses and effects.

Strength

2400 UNIT

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

HYQVIA 2400 Unit is primarily used to enhance the dispersion and absorption of other drugs administered subcutaneously. Hyaluronidase (human recombinant) works by breaking down hyaluronic acid in the skin, which can help other medications spread more evenly. This can be particularly useful for patients who need to administer multiple medications subcutaneously.

Side Effects

Common effects of HYQVIA 2400 Unit may include localized reactions at the injection site, such as redness, swelling, or itching. Some users might also experience mild discomfort or bruising. These effects are generally temporary and should subside on their own.

Precautions & Warnings

HYQVIA 2400 Unit should be handled with care. It is important to follow proper injection techniques to minimize the risk of infection or other complications. Always consult a healthcare provider before starting any new medication regimen.

Avoid Interactions

HYQVIA 2400 Unit may interact with other medications, particularly those that are also administered subcutaneously. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always follow the advice of a healthcare professional.

Frequently Asked Questions

HYQVIA 2400 Unit is used to facilitate the absorption of other medications administered subcutaneously by breaking down hyaluronic acid in the skin.

HYQVIA 2400 Unit is administered subcutaneously. It is important to follow the instructions provided by a healthcare provider for proper administration.

Common side effects may include localized reactions at the injection site, such as redness, swelling, or itching. These effects are usually temporary.

HYQVIA 2400 Unit may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Precautions include following proper injection techniques and consulting a healthcare provider to avoid potential complications or interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.